{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:50:12Z","timestamp":1790394612163,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2014,3,18]],"date-time":"2014-03-18T00:00:00Z","timestamp":1395100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,3,18]],"date-time":"2014-03-18T00:00:00Z","timestamp":1395100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1038\/leu.2014.106","type":"journal-article","created":{"date-parts":[[2014,4,11]],"date-time":"2014-04-11T11:39:54Z","timestamp":1397216394000},"page":"2049-2059","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":88,"title":["Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma"],"prefix":"10.1038","volume":"28","author":[{"given":"A","family":"Moros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Saborit-Villarroya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Montraveta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Balsas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Sandy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Wiestner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Normant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Campo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"P\u00e9rez-Gal\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Colomer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Rou\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,3,18]]},"reference":[{"key":"BFleu2014106_CR1","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1172\/JCI61272","volume":"122","author":"P Jares","year":"2012","unstructured":"Jares P, Colomer D, Campo E . Molecular pathogenesis of mantle cell lymphoma. J Clin Invest 2012; 122: 3416\u20133423.","journal-title":"J Clin Invest"},{"key":"BFleu2014106_CR2","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","volume":"117","author":"P Perez-Galan","year":"2011","unstructured":"Perez-Galan P, Dreyling M, Wiestner A . Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 2011; 117: 26\u201338.","journal-title":"Blood"},{"key":"BFleu2014106_CR3","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1158\/1078-0432.CCR-07-2218","volume":"14","author":"RZ Orlowski","year":"2008","unstructured":"Orlowski RZ, Kuhn DJ . Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 2008; 14: 1649\u20131657.","journal-title":"Clin Cancer Res"},{"key":"BFleu2014106_CR4","doi-asserted-by":"publisher","first-page":"4053","DOI":"10.2174\/1381612811319220014","volume":"19","author":"W Xolalpa","year":"2013","unstructured":"Xolalpa W, Perez-Galan P, Rodriguez MS, Roue G . Targeting the ubiquitin proteasome system: beyond proteasome inhibition. Curr Pharm Des 2013; 19: 4053\u20134093.","journal-title":"Curr Pharm Des"},{"key":"BFleu2014106_CR5","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","volume":"24","author":"RI Fisher","year":"2006","unstructured":"Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de VS et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006; 24: 4867\u20134874.","journal-title":"J Clin Oncol"},{"key":"BFleu2014106_CR6","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1093\/annonc\/mdn656","volume":"20","author":"A Goy","year":"2009","unstructured":"Goy A, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de VS et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2009; 20: 520\u2013525.","journal-title":"Ann Oncol"},{"key":"BFleu2014106_CR7","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1365-2141.2008.07466.x","volume":"145","author":"OA O'Connor","year":"2009","unstructured":"O'Connor OA, Moskowitz C, Portlock C, Hamlin P, Straus D, Dumitrescu O et al. Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial. Br J Haematol 2009; 145: 34\u201339.","journal-title":"Br J Haematol"},{"key":"BFleu2014106_CR8","doi-asserted-by":"publisher","first-page":"5101","DOI":"10.1158\/1078-0432.CCR-10-3367","volume":"17","author":"MA Weniger","year":"2011","unstructured":"Weniger MA, Rizzatti EG, Perez-Galan P, Liu D, Wang Q, Munson PJ et al. Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma. Clin Cancer Res 2011; 17: 5101\u20135112.","journal-title":"Clin Cancer Res"},{"key":"BFleu2014106_CR9","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1182\/blood-2010-04-278853","volume":"117","author":"G Roue","year":"2011","unstructured":"Roue G, Perez-Galan P, Mozos A, Lopez-Guerra M, Xargay-Torrent S, Rosich L et al. The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP\/Grp78. Blood 2011; 117: 1270\u20131279.","journal-title":"Blood"},{"key":"BFleu2014106_CR10","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1182\/blood-2010-02-269514","volume":"117","author":"P Perez-Galan","year":"2011","unstructured":"Perez-Galan P, Mora-Jensen H, Weniger MA, Shaffer AL III, Rizzatti EG, Chapman CM et al. Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation. Blood 2011; 117: 542\u2013552.","journal-title":"Blood"},{"key":"BFleu2014106_CR11","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/ng1097-226","volume":"17","author":"S Iida","year":"1997","unstructured":"Iida S, Rao PH, Butler M, Corradini P, Boccadoro M, Klein B et al. Deregulation of MUM1\/IRF4 by chromosomal translocation in multiple myeloma. Nat Genet 1997; 17: 226\u2013230.","journal-title":"Nat Genet"},{"key":"BFleu2014106_CR12","doi-asserted-by":"publisher","first-page":"e22628","DOI":"10.1371\/journal.pone.0022628","volume":"6","author":"S Pathak","year":"2011","unstructured":"Pathak S, Ma S, Trinh L, Eudy J, Wagner KU, Joshi SS et al. IRF4 is a suppressor of c-Myc induced B cell leukemia. PLoS One 2011; 6: e22628.","journal-title":"PLoS One"},{"key":"BFleu2014106_CR13","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nature07064","volume":"454","author":"AL Shaffer","year":"2008","unstructured":"Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G, Xiao W et al. IRF4 addiction in multiple myeloma. Nature 2008; 454: 226\u2013231.","journal-title":"Nature"},{"key":"BFleu2014106_CR14","doi-asserted-by":"publisher","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","volume":"31","author":"A Goy","year":"2013","unstructured":"Goy A, Sinha R, Williams ME, Kalayoglu Besisik S, Drach J, Ramchandren R et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol 2013; 31: 3688\u20133695.","journal-title":"J Clin Oncol"},{"key":"BFleu2014106_CR15","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/bjh.12449","volume":"162","author":"JM Vose","year":"2013","unstructured":"Vose JM, Habermann TM, Czuczman MS, Zinzani PL, Reeder CB, Tuscano JM et al. Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation. Br J Haematol 2013; 162: 639\u2013647.","journal-title":"Br J Haematol"},{"key":"BFleu2014106_CR16","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","volume":"22","author":"TE Witzig","year":"2011","unstructured":"Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2011; 22: 1622\u20131627.","journal-title":"Ann Oncol"},{"key":"BFleu2014106_CR17","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1093\/annonc\/mdt366","volume":"24","author":"PL Zinzani","year":"2013","unstructured":"Zinzani PL, Vose JM, Czuczman MS, Reeder CB, Haioun CF, Polikoff JF et al. Long-term follow-up of lenalidomide in relapsed\/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. Ann Oncol 2013; 24: 2892\u20132897.","journal-title":"Ann Oncol"},{"key":"BFleu2014106_CR18","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","volume":"13","author":"M Wang","year":"2012","unstructured":"Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial. Lancet Oncol 2012; 13: 716\u2013723.","journal-title":"Lancet Oncol"},{"key":"BFleu2014106_CR19","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/j.1365-2141.2011.08689.x","volume":"154","author":"A Lopez-Girona","year":"2011","unstructured":"Lopez-Girona A, Heintel D, Zhang LH, Mendy D, Gaidarova S, Brady H et al. Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response. Br J Haematol 2011; 154: 325\u2013336.","journal-title":"Br J Haematol"},{"key":"BFleu2014106_CR20","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ccr.2012.05.024","volume":"21","author":"Y Yang","year":"2012","unstructured":"Yang Y, Shaffer AL III, Emre NC, Ceribelli M, Zhang M, Wright G et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 2012; 21: 723\u2013737.","journal-title":"Cancer Cell"},{"key":"BFleu2014106_CR21","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/bjh.12172","volume":"160","author":"LH Zhang","year":"2013","unstructured":"Zhang LH, Kosek J, Wang M, Heise C, Schafer PH, Chopra R . Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression. Br J Haematol 2013; 160: 487\u2013502.","journal-title":"Br J Haematol"},{"key":"BFleu2014106_CR22","doi-asserted-by":"publisher","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","volume":"118","author":"YX Zhu","year":"2011","unstructured":"Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van WS et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011; 118: 4771\u20134779.","journal-title":"Blood"},{"key":"BFleu2014106_CR23","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein S et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 4th edn. International Agency for Research on Cancer: Lyon, France, 2008."},{"key":"BFleu2014106_CR24","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/j.0105-2896.2006.00373.x","volume":"210","author":"AL Shaffer","year":"2006","unstructured":"Shaffer AL, Wright G, Yang L, Powell J, Ngo V, Lamy L et al. A library of gene expression signatures to illuminate normal and pathological lymphoid biology. Immunol Rev 2006; 210: 67\u201385.","journal-title":"Immunol Rev"},{"key":"BFleu2014106_CR25","doi-asserted-by":"publisher","first-page":"5278","DOI":"10.1158\/1078-0432.CCR-12-0351","volume":"18","author":"L Rosich","year":"2012","unstructured":"Rosich L, Xargay-Torrent S, Lopez-Guerra M, Campo E, Colomer D, Roue G . Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma. Clin Cancer Res 2012; 18: 5278\u20135289.","journal-title":"Clin Cancer Res"},{"key":"BFleu2014106_CR26","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","volume":"146","author":"JE Delmore","year":"2011","unstructured":"Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011; 146: 904\u2013917.","journal-title":"Cell"},{"key":"BFleu2014106_CR27","doi-asserted-by":"publisher","first-page":"16669","DOI":"10.1073\/pnas.1108190108","volume":"108","author":"JA Mertz","year":"2011","unstructured":"Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci USA 2011; 108: 16669\u201316674.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2014106_CR28","doi-asserted-by":"publisher","first-page":"6927","DOI":"10.1073\/pnas.1120422109","volume":"109","author":"BN Devaiah","year":"2012","unstructured":"Devaiah BN, Lewis BA, Cherman N, Hewitt MC, Albrecht BK, Robey PG et al. BRD4 is an atypical kinase that phosphorylates Serine2 of the RNA polymerase II carboxy-terminal domain. Proc Natl Acad Sci USA 2012; 109: 6927\u20136932.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2014106_CR29","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/j.cell.2013.05.041","volume":"153","author":"B King","year":"2013","unstructured":"King B, Trimarchi T, Reavie L, Xu L, Mullenders J, Ntziachristos P et al. The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. Cell 2013; 153: 1552\u20131566.","journal-title":"Cell"},{"key":"BFleu2014106_CR30","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/454172a","volume":"454","author":"JD Shaughnessy","year":"2008","unstructured":"Shaughnessy JD . Cancer: an unexpected addiction. Nature 2008; 454: 172\u2013173.","journal-title":"Nature"},{"key":"BFleu2014106_CR31","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/leu.2008.320","volume":"23","author":"AL Feldman","year":"2009","unstructured":"Feldman AL, Law M, Remstein ED, Macon WR, Erickson LA, Grogg KL et al. Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas. Leukemia 2009; 23: 574\u2013580.","journal-title":"Leukemia"},{"key":"BFleu2014106_CR32","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1126\/science.275.5299.540","volume":"275","author":"HW Mittrucker","year":"1997","unstructured":"Mittrucker HW, Matsuyama T, Grossman A, Kundig TM, Potter J, Shahinian A et al. Requirement for the transcription factor LSIRF\/IRF4 for mature B and T lymphocyte function. Science 1997; 275: 540\u2013543.","journal-title":"Science"},{"issue":"39","key":"BFleu2014106_CR33","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/jncimonographs\/lgn011","volume":"2008","author":"A. Dib","year":"2008","unstructured":"Dib A, Gabrea A, Glebov OK, Bergsagel PL, Kuehl WM . Characterization of MYC translocations in multiple myeloma cell lines. J Natl Cancer Inst Monogr 2008, 25\u201331.","journal-title":"JNCI Monographs"},{"issue":"5","key":"BFleu2014106_CR34","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.semcancer.2011.09.007","volume":"21","author":"Cristina Royo","year":"2011","unstructured":"Royo C, Salaverria I, Hartmann EM, Rosenwald A, Campo E, Bea S . The complex landscape of genetic alterations in mantle cell lymphoma. Semin Cancer Biol 21: 322\u2013334.","journal-title":"Seminars in Cancer Biology"},{"key":"BFleu2014106_CR35","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1124\/jpet.110.170555","volume":"335","author":"DM Clausen","year":"2010","unstructured":"Clausen DM, Guo J, Parise RA, Beumer JH, Egorin MJ, Lazo JS et al. In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc\/Max dimerization. J Pharmacol Exp Ther 2010; 335: 715\u2013727.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFleu2014106_CR36","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","volume":"153","author":"J Loven","year":"2013","unstructured":"Loven J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013; 153: 320\u2013334.","journal-title":"Cell"},{"key":"BFleu2014106_CR37","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1158\/1078-0432.CCR-12-3066","volume":"19","author":"Z Cheng","year":"2013","unstructured":"Cheng Z, Gong Y, Ma Y, Lu K, Lu X, Pierce LA et al. Inhibition of BET bromodomain targets genetically diverse glioblastoma. Clin Cancer Res 2013; 19: 1748\u20131759.","journal-title":"Clin Cancer Res"},{"key":"BFleu2014106_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbrc.2012.10.112","volume":"429","author":"O Goupille","year":"2012","unstructured":"Goupille O, Penglong T, Lefevre C, Granger M, Kadri Z, Fucharoen S et al. BET bromodomain inhibition rescues erythropoietin differentiation of human erythroleukemia cell line UT7. Biochem Biophys Res Commun 2012; 429: 1\u20135.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFleu2014106_CR39","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1182\/blood-2012-02-413021","volume":"120","author":"CJ Ott","year":"2012","unstructured":"Ott CJ, Kopp N, Bird L, Paranal RM, Qi J, Bowman T et al. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood 2012; 120: 2843\u20132852.","journal-title":"Blood"},{"key":"BFleu2014106_CR40","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1038\/leu.2013.94","volume":"27","author":"X Zhao","year":"2013","unstructured":"Zhao X, Lwin T, Zhang X, Huang A, Wang J, Marquez VE et al. Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity. Leukemia 2013; 27: 2341\u20132350.","journal-title":"Leukemia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2014106.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2014106","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/leu.2014.106","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/leu2014106.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:08:35Z","timestamp":1648742915000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2014106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,18]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["BFleu2014106"],"URL":"https:\/\/doi.org\/10.1038\/leu.2014.106","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,18]]},"assertion":[{"value":"2 January 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P Sandy and E Normant are employees with stock ownership in Constellation Pharmaceuticals, Inc. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}